RE: RNS Interim Results6 Dec 2019 07:39
I agree Chester, not sure what's not to like...cash coming in from Fosun, many buns in the oven, increased number of patients etc etc...Stifel's research as usual very optimistic :
Summary
Alongside 1H20 results which are in-line with our expectations, ReNeuron has announced important updates to the trial protocols for its two clinical assets. Based on encouraging data thus far with the retinal programme (hRPC) the Phase IIa efficacy portion of the ongoing trial is being extended to enable longer-term follow-up data on a larger group of patients in 2020. With a more robust data set in hand this could subsequently enable a single pre-approval study for the product. As for CTX in chronic stroke disability, in order to encourage and accelerate recruitment into the trial, the treatment-to-placebo ratio will increase to 2:1 from 1:1, enabling more patients to receive active therapy (c. 84 vs 55 patients), while also widening the treatment window to 6-24 months post-stroke (vs 6-12 months previously). ReNeuron ended 1H FY20 (30 Sep 2019) with £21.3m in cash (vs our £21.5m estimate), sufficient to generate more meaningful data from the retinal programme by mid-2020. We continue to believe ReNeuron is a misspriced stock with an attractive risk-reward profile, and therefore reiterate our Buy rating and £6.90 buy target...the only thought I have is whether we have a further fund raise before we do another Fosun-type fund raise...but even if we do, I'm pretty relaxed...the stars I think are aligning very nicely.